Preferred Label : CEA-MUC-1-TRICOM Vaccine CV301;
NCIt synonyms : PANVAC; MVA-BN/Fowlpox-CEA-MUC-1-TRICOM Vaccine CV301;
NCIt definition : A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which
is comprised of a proprietary version of the recombinant vaccinia viral vector, modified
vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used
for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic
antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing
co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory
and antineoplastic activities. The administration of the vaccinia priming dose is
followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine
CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs)
and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing
tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated
tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor,
the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain
cancers.;
Molecule name : CVAC-301; CV301-V/F; CV-301;
NCI Metathesaurus CUI : CL513447;
Origin ID : C131129;
UMLS CUI : C4329594;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
